LANTERN PHARMA INC
LTRNNASDAQTrading Snapshot
- Day Range
- $0.64 – $0.82
- 52-Week Range
- $0.59 – $4.34
- Volume (shares)
- 601,932
- Avg Volume (shares)
- —
- Shares Outstanding
- 14.9M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -0.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.50
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.1%
LANTERN PHARMA INC
LTRN
StockOtter · stockotter.spaceAbout LANTERN PHARMA INC
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering.
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern”, the “Company” or “we”), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology t
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology t
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an AI‑driven precision oncology company transforming the cost, pace, and timeline of oncology drug discovery and development, today announced that the United S